The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
about
Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltrationCopper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.Copper and angiogenesis: unravelling a relationship key to cancer progression.Wilson disease and hepatocellular carcinoma.Antiangiogenic therapy through copper chelation.Complex N-acetylation of triethylenetetramine.Pharmacological activity of metal binding agents that alter copper bioavailability.Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.New applications of old metal-binding drugs in the treatment of human cancer.Dithiocarbamate-based coordination compounds as potent proteasome inhibitors in human cancer cells.Novel metals and metal complexes as platforms for cancer therapyNitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistryBioavailable copper modulates oxidative phosphorylation and growth of tumors.Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer with copper (II)-64 chloride.The many "faces" of copper in medicine and treatment.Metal-mediated DNA damage and cell death: mechanisms, detection methods, and cellular consequences.Targeting copper in cancer therapy: 'Copper That Cancer'.Low-glucose conditions of tumor microenvironment enhance cytotoxicity of tetrathiomolybdate to neuroblastoma cells.A benzothiazole alkyne fluorescent sensor for Cu detection in living cell.Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin ResistanceMetabolomic analysis of rat serum in streptozotocin-induced diabetes and after treatment with oral triethylenetetramine (TETA).Combination Therapy with Low Copper Diet, Penicillamine and Gamma Knife Radiosurgery Reduces VEGF and IL-8 In Patients with Recurrent GlioblastomaExploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress.Synthesis, characterization, and anticancer activity of two mixed ligand copper(ii) complexes by regulating the VEGF/VEGFR2 signaling pathway.Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo.In vitro sensing of Cu(+) through a green fluorescence rise of pyranine.Hepatobiliary malignancies in Wilson disease.Complex inhibition of tyrosinase by thiol-composed Cu2+ chelators: a clue for designing whitening agents.
P2860
Q27307762-F9451726-BF84-4130-B1DE-4D4E90E03AD1Q34458507-A44023C2-B919-4BA4-8730-274DB15ADF70Q34503515-382F1CBC-CFC1-4E23-9FC1-DF9D3C541F0BQ34632151-9C18B2E2-89AA-4CB5-A7F5-2CDCAEBB8B58Q35143913-55E763C7-C9D8-4C90-B7DB-61F2772BD991Q35579534-33FD6F39-C6E8-4925-A77E-05EC95D65952Q35587484-27BD38DE-F3E0-4DB6-896D-F5A2736E5079Q35800509-3F5AF5DB-D23F-43C9-A169-0C391CA99EA3Q36822739-D76F84A2-45CA-4803-A343-2BDB4614A21DQ36837031-FF135000-0B09-4D6A-B622-958A7DB0D947Q37137649-2D92D1DF-B959-40AB-BBE0-6DF9788F988EQ37148781-28C2EE47-6E68-4CD7-90EC-03E97734DC80Q37206068-A1C143DB-B7E7-4057-A37D-B732D8347646Q37353035-43B8C17B-AC29-43CF-AECA-66E0D9AAF53FQ37577907-341C5299-09B9-4AC1-967C-59BFCFA59396Q38205742-FDFCF62F-3F58-4949-B043-8823BA9478B7Q38208675-ADC422BA-FC9D-49D6-AB39-DDB858ED69C9Q38575035-5DF2F8D8-786F-41F1-A0EE-717D1E6FB4F3Q39125256-8E4A6970-38FF-4947-A8B8-1EABCF62C9A9Q40922958-F9598E8E-90CD-4E4B-AD71-9A65D661963DQ41200507-338CB361-FE1F-4794-862B-EF230F5E8EEFQ41439806-6EF2E3AF-0E74-4094-ACDC-F568E9A245C2Q42096841-569A8E89-C780-4C73-A995-F5E01D540C3AQ42672703-BF02811C-BB14-4B85-BDC0-03C9B980689BQ42708068-607BEBCC-E85E-4910-A8EC-23625591A373Q46387857-366E5776-B1AF-4D93-9DCA-DFFA79E040ADQ47397719-C570D7A1-7024-4B42-89B6-B3C5906CDB98Q48962335-E91D8332-CA23-43DF-8AEC-F399A3FB5A3DQ50452330-C3C48C24-C971-4567-88CE-523263463F69Q50616937-6AB2EC26-86DB-4459-9F41-702EB67D2A84Q51934718-26A02832-51B0-4845-9688-AD45950738FE
P2860
The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
The copper-chelating agent, tr ...... epatocellular carcinoma cells.
@en
type
label
The copper-chelating agent, tr ...... epatocellular carcinoma cells.
@en
prefLabel
The copper-chelating agent, tr ...... epatocellular carcinoma cells.
@en
P2093
P2860
P50
P356
P1476
The copper-chelating agent, tr ...... hepatocellular carcinoma cells
@en
P2093
H Tsujinoue
M S De Lorenzo
S Kuriyama
T Nakatani
P2860
P304
P356
10.1002/IJC.1537
P577
2001-12-01T00:00:00Z